Skip to Content
Merck
  • Elevated intracellular cAMP concentration mediates growth suppression in glioma cells.

Elevated intracellular cAMP concentration mediates growth suppression in glioma cells.

Biochemical pharmacology (2020-01-29)
Dewi Safitri, Matthew Harris, Harriet Potter, Ho Yan Yeung, Ian Winfield, Liliya Kopanitsa, Fredrik Svensson, Taufiq Rahman, Matthew T Harper, David Bailey, Graham Ladds
ABSTRACT

Supressed levels of intracellular cAMP have been associated with malignancy. Thus, elevating cAMP through activation of adenylyl cyclase (AC) or by inhibition of phosphodiesterase (PDE) may be therapeutically beneficial. Here, we demonstrate that elevated cAMP levels suppress growth in C6 cells (a model of glioma) through treatment with forskolin, an AC activator, or a range of small molecule PDE inhibitors with differing selectivity profiles. Forskolin suppressed cell growth in a PKA-dependent manner by inducing a G2/M phase cell cycle arrest. In contrast, trequinsin (a non-selective PDE2/3/7 inhibitor), not only inhibited cell growth via PKA, but also stimulated (independent of PKA) caspase-3/-7 and induced an aneuploidy phenotype. Interestingly, a cocktail of individual PDE 2,3,7 inhibitors suppressed cell growth in a manner analogous to forskolin but not trequinsin. Finally, we demonstrate that concomitant targeting of both AC and PDEs synergistically elevated intracellular cAMP levels thereby potentiating their antiproliferative actions.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
BAY 73-6691, ≥98% (HPLC), powder
Sigma-Aldrich
(Tyr[SO3H]27)Cholecystokinin fragment 26-33 Amide, ≥97% (HPLC), powder
Sigma-Aldrich
YC-1, powder
Sigma-Aldrich
Adenosine 3′,5′-cyclic monophosphate tris salt, ≥97% (HPLC), powder
Sigma-Aldrich
CE3F4, ≥98% (HPLC)